胸腺肽α1联合干扰素α-1b、利巴韦林治疗老年慢性丙型肝炎患者的临床观察(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 观察胸腺肽α1联合干扰素α-1b、利巴韦林治疗老年慢性丙型肝炎患者的治疗效果和安全性。 方法 将72例老年慢性丙型肝炎患者分为A组和B组，A组42例给予胸腺肽α1联合干扰素α-1b 40 μg和利巴韦林胶囊；B组30例给予干扰素α-1b 40 μg和利巴韦林胶囊，两组均治疗48周，随访24周。 结果 A组患者治疗结束时应答率为59.0%，高于B组(46.4%)：随访24周A组患者复发率为7.7%，明显低于B组(14.3%)，差异有统计学意义(P < 0.05或P < 0.01)；A组对药物具有较好的耐受性，其不良反应发生率明显低于B组(P < 0.05或P < 0.01)。 结论 胸腺肽α1联合干扰素α-1b、利巴韦林治疗老年慢性丙型肝炎具有较好的治疗效果，且副作用较轻。
[关键词] 慢性丙型肝炎：干扰素α-1b；利巴韦林；胸腺肽α1；老年
[中图分类号] R575.2 [文献标识码] A [文章编号] 1673-7210(2012)08(c)-0080-03
Efficiency of thymosin α1 comblined interferon α-1b with Ribavirin in the treatment of elderly patients with chronic hepatitis C
CUI Kun1,2 FAN Gongren2 XIONG Jinhua2 JI Shengjie1 HOU Baoquan1 GONG Xinhui1 LI Yizhuo1 GAO Hui1 ZHONG Fang1
1.Department of Hepatopathy, Changzheng People's Hospital of Shangqiu City, He'nan Province, Shangqiu 476000, China; 2.Hepatopathy Treatment Center of Whole Army, Beijing Military General Hospital, Beijing 100700, China
[Abstract] Objective To evaluate the safety and effect of thymoison α1 combined interferon α-1b with Ribavirin as antiviral therapy for the elderly patients with chronic hepatitis C. Methods 72 patients with chronic hepatitis C virus (HCV) were divided into group A and B; 42 patients were given thymoison α1 combined interferon α-1b and Ribavirin in group A, 30 patients were given thymoison α1 combined interferon α-1b as control group, all patients were treated for 48 weeks and followed up for 24 weeks after treatment. Results At the end of treatment, the ETVR was 59 ......
您现在查看是摘要介绍页，详见PDF附件(3322kb)。